Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipili
PRINCETON, N.J. , June 04 /Businesswire/ - $BMY announces four-year data to be presented at #ASCO23 from Phase 3 trial with dual immunotherapy-based combination in metastatic non-small cell #lungcancer. #LCSM